Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Google Secures Pentagon AI Deal for Classified Projects 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
SAN DIEGO, May 02, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2017 financial results after the market closes on Tuesday, May 9, 2017. The press release will be followed by a conference call on Wednesday, May 10, 2017 at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 14568675. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on May 10, 2017 to 7:30 p.m. ET on May 17, 2017. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 14568675.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact: Vital Therapies, Inc. Al Kildani Vice President, Investor Relations and Business Development 858-673-6840 [email protected]
